0001193125-26-148853
SEC filingOrthofix Medical Inc. reported preliminary Q1 2026 net sales of $196.7 million (up 0.4% YoY), reaffirmed full-year 2026 guidance of $850–$860 million in net sales and $95–$98 million in non-GAAP adjusted EBITDA, and announced the departure of President, Global Spine Max Reinhardt effective June 12, 2026.
Orthofix’s Q1 2026 results reflect early execution against its 2026 strategic priorities: distributor optimization, 7D™ navigation commercialization, and portfolio simplification. The $196.7 million in reported net sales — up 0.4% YoY on a constant currency basis — includes $0.3 million from discontinued M6 disc sales, which declined sharply from $4.4 million in Q1 2025. Excluding that legacy line, pro forma net sales rose 3% YoY, signaling resilience in core spine hardware and biologics amid ongoing channel transitions. Management attributes this to successful distributor onboarding and early traction with high-value initiatives, particularly around the 7D FLASH™ Navigation System. The reaffirmation of full-year guidance — $850–$860 million in net sales and $95–$98 million in non-GAAP adjusted EBITDA — underscores confidence in sustained execution, with implied 5.5% pro forma constant currency growth and 70 bps EBITDA margin expansion. Critically, the leadership realignment eliminates a layer of management by dissolving the President, Global Spine role and consolidating accountability under CEO Massimo Calafiore. This structural shift, paired with expanded mandates for Shaeffer Bannigan (overall Spine strategy), Mark Sienkiewicz (U.S. implant commercial execution), and John Winge (7D navigation adoption), signals intensified focus on decision speed and commercial discipline. Max Reinhardt’s departure is not framed as disruptive but as an intentional step to align leadership with the company’s sharpened strategic focus on profitable growth, innovation velocity, and cross-portfolio synergies — especially between Biologics (now led by Patrick Fisher) and Limb Reconstruction. With Q1 results validating near-term execution and the leadership structure now simplified, Orthofix positions itself to scale its commercial engine ahead of anticipated 2026 product launches, while maintaining disciplined capital allocation reflected in the expectation of positive free cash flow for the full year, excluding legal settlements.